NCT05615415View on ClinicalTrials.gov

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

Active, not recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions
DRUG

PET Tracer

Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.

DRUG

MRI Tracer

Injected via intravenous catheter during PET-MR scanning.

DEVICE

3T PET/MRI

Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER